

# **Zulresso Enrollment Form**

Fax Referral To: 1-800-323-2445 Phone: 1-800-678-1831 Email Referral To: Customer.ServiceFax@CVSHealth.com

	N (Complete or include demograph	hic sheet)				
Patient Name:	Address:		City, State, ZIP:			
Preferred Contact Methods:	Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below)					
Note: Carrier charges may appl	y. If unable to contact via text or ema	ail, Specialty Pharma	cy will attempt to co	ntact by phone.		
Primary Phone:	Alternate Phone:	DOB:	G	ender: 🗌 Male 🗌 Female		
Email:	Last Four of	SSN: F	Primary Language: _			
PRESCRIBER INFORMA	ATION					
Prescriber's Name:	1	Practice Name:				
	City, State, ZIP:					
	NPI #:					
		Contact's Phone:				
	ATION Please fax copy of prescription					
Pharmacy Plan Name:			Pharmacy Plan	Telephone:		
Pharmacy Plan Name:			Pharmacy Plan	Telephone:		
Pharmacy Plan Name: Policy ID:	Group		Pharmacy Plan	Telephone:		
Pharmacy Plan Name: Policy ID:  DIAGNOSIS AND CLIN	ICAL INFORMATION	o #: F	Pharmacy Plan	Telephone:		
Pharmacy Plan Name:Policy ID:  DIAGNOSIS AND CLIN Needs by Date:	Group  ICAL INFORMATION  Ship to: Infusion Site Address:	o #: F	Pharmacy Plan RX BIN #:	Telephone: _ RX PCN #:		
Pharmacy Plan Name:Policy ID:  DIAGNOSIS AND CLIN Needs by Date: Note: Zulresso is available only	ICAL INFORMATION  Ship to: Infusion Site Address: through a restricted distribution pro	o #: F	Pharmacy Plan RX BIN #: .RESSO REMS becau	Telephone:RX PCN #:use of the <b>risk of serious</b>		
Pharmacy Plan Name:Policy ID:  DIAGNOSIS AND CLIN Needs by Date: Note: Zulresso is available only harm resulting from excessive	Group  ICAL INFORMATION  _ Ship to: Infusion Site Address: through a restricted distribution pro e sedation and sudden loss of cons	o #: F	Pharmacy Plan RX BIN #: .RESSO REMS becau	Telephone:RX PCN #:use of the <b>risk of serious</b>		
Pharmacy Plan Name:Policy ID:  DIAGNOSIS AND CLIN Needs by Date: Note: Zulresso is available only harm resulting from excessive infusion only in a certified Hea  Will REMS certified health care	Group  ICAL INFORMATION  _ Ship to: Infusion Site Address: through a restricted distribution pro e sedation and sudden loss of cons	gram called the ZUL sciousness during the	Pharmacy Plan RX BIN #:  RESSO REMS becau he Zulresso infusion ration:	Telephone:RX PCN #: use of the risk of serious n. Zulresso is intended for		
Pharmacy Plan Name:Policy ID:  DIAGNOSIS AND CLIN Needs by Date: Note: Zulresso is available only harm resulting from excessive infusion only in a certified Hea  Will REMS certified health care	Group  ICAL INFORMATION  Ship to: Infusion Site Address: through a restricted distribution pro e sedation and sudden loss of cons alth Care Setting.  facility dilute and prepare product for	gram called the ZUL sciousness during the	Pharmacy Plan RX BIN #:  RESSO REMS becau he Zulresso infusion ration:	Telephone:RX PCN #: use of the risk of serious n. Zulresso is intended for		
Pharmacy Plan Name:Policy ID:  DIAGNOSIS AND CLIN Needs by Date: Note: Zulresso is available only harm resulting from excessive infusion only in a certified Hea  Will REMS certified health care If 'No,' does REMS certified hea	Group  ICAL INFORMATION  Ship to: Infusion Site Address: through a restricted distribution pro e sedation and sudden loss of cons alth Care Setting.  facility dilute and prepare product for	gram called the ZUL sciousness during the correct or infusion administration armacy to dilute and	Pharmacy Plan RX BIN #:  RESSO REMS becau he Zulresso infusion ration: prepare Zulresso?	Telephone:RX PCN #: use of the risk of serious n. Zulresso is intended for		
Pharmacy Plan Name:Policy ID:  DIAGNOSIS AND CLIN Needs by Date: Note: Zulresso is available only harm resulting from excessive infusion only in a certified Heat Will REMS certified health care If 'No,' does REMS certified heat Diagnosis (ICD-10): F53.0 Postpartum Depressi	Group  ICAL INFORMATION  Ship to: Infusion Site Address: through a restricted distribution pro e sedation and sudden loss of cons alth Care Setting.  facility dilute and prepare product for the sedation and sudden loss of consecutive sedation.	gram called the ZUL sciousness during the crimination administrem armacy to dilute and Description:	Pharmacy Plan RX BIN #:  RESSO REMS becau he Zulresso infusion ration: prepare Zulresso?	Telephone:RX PCN #: use of the risk of serious n. Zulresso is intended for		

### TREATMENT INFORMATION FOR PRESCRIBERS

## Before submitting this form, please ensure:

- · Provider identifies whether or not specialty pharmacy will dispense diluted and prepared Zulresso for infusion administration
  - Note: If dilution and preparation of Zulresso is required, please ensure prescription order also covers a Curlin 6000
     CMS ambulatory infusion pump and tubing
- · Copies of the health insurance and prescription drug coverage cards are provided

Continued on next page

## **Zulresso Enrollment Form**

Please complete Patient and Prescriber information				
Patient Name:	Patient DOB:			
Prescriber Name:	Prescriber Phone:			

#### TREATMENT INFORMATION FOR PRESCRIBERS continued

#### **Zulresso prescribing highlights**

- Zulresso is administered as a continuous IV infusion over 60 hours as follows:
  - o 0 to 4 hours: Initiate with a dosage of 30 mcg/kg/hour
  - o 4 to 24 hours: Increase dosage to 60 mcg/kg/hour
  - 24 to 52 hours: Increase dosage to 90 mcg/kg/hour (alternatively consider a dosage of 60 mcg/kg/hour for those who do not tolerate 90 mcg/kg/hour)
  - o 52 to 56 hours: Decrease dosage to 60 mcg/kg/hour
  - o 56 to 60 hours: Decrease dosage to 30 mcg/kg/hour
- Prior to infusion, each vial of Zulresso must be diluted with 40ml Sterile Water for Injection and 40ml of 0.9 % Sodium Chloride Injection for a total volume of 100ml to achieve a concentration of 1mg/ml.
- After dilution, the product can be stored in infusion bags under refrigerated conditions for up to 96 hours. However, given that the diluted product can be used for only 12 hours at room temperature, each 60-hour infusion will require the preparation of at least 5 infusion bags.

For additional information, please refer to full prescribing information: Zulresso Prescribing Information

#### PRESCRIPTION INFORMATION

NOTE: The prescription form below should only be used if permitted by the applicable law in your state and if you are not required by law to use an official/tamper-evident prescription form. The prescriber should include all required elements of a controlled substance prescription.

controlled substance prescription.					
Patient Name (First and Last):		Patient Date of Birth	:		
Patient Address:					
Drug Name, strength, and dosage for	m:				
Directions/Sig:					
Quantity Authorized (Numeric)	(Written) _				
Physician Name:		Physician DEA #:	<del></del>		
Physician Address:					
PHYSICIAN SIGNATURE REQUIRED  PRODUCT SUBSTITUTION PERMITTED (Date) DISPENSE AS WRITTEN (Date)					
x	····	x			

# **Prescriber Signature Required (no stamps)**

Please note regulations around transmission of prescriptions for controlled substances vary state by state.

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature. CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates. ©2021 CVS Pharmacy, Inc. or one of its affiliates. 75-49131A 020921